Zyrosa Tablets / Film-coated

Rosuvastatin

12mg

Oman Pharmaceutical Products

Pack size	28's (14's Blister x 2)
Dispensing mode	POM
Source	OMAN
Agent	Muscat Pharmaceutical Trading L.L.C.
Retail Price	79.00 AED

Available as:

10mg - Tablets / Film-coated

Indications

Zyrosa Tablets / Film-coated is used for: Hyperlipidaemias, Primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia), mixed dyslipidaemia, homozygous familial hypercholesterolaemia, Stroke prevention

Adult Dose

Oral Hypercholesterolemia, Hypertriglyceridemia, hyperlipidemia, mixed dyslipidemiaProphylaxis of cardiovascular events in high-risk patients Adult: Initially, 5 or 10 mg once daily, may increase dose at 4-wkly intervals to 20 mg daily if necessary. Max: 40 mg once daily. Active liver disease: Use is contraindicated

Child Dose

Oral Child Heterozygous familial hypercholesterolaemia: >10 yr Initially, 5 mg once daily, may be adjusted at intervals of at least 4 wk. Max: 20 mg once daily.

Renal Dose

Renal impairment Severe (CrCl <30 mL/min/1.73m²) and not on hemodialysis: Decrease starting dose to 5 mg PO qDay; not to exceed 10 mg PO qDay CrCl>30mL/min/1.73m²: Dose adjustment not necessary

Administration

May be taken with or without food.

Contra Indications

Severe renal impairment, active liver disease, unexplained persistent elevations of serum transaminases; hypersensitivity. Pregnancy, lactation.

Precautions

Patients w/ predisposing factors for myopathy (e.g. untreated hypothyroidism, renal impairment), history of chronic liver disease and alcoholism. Monitoring Parameters Monitor creatine kinase (CK) periodically and LFT. Discontinue treatment if there is significant or persistent increase in CK levels, serum aminotransferase levels or evidence of myopathy. Lactation Contraindicated

Pregnancy-Lactation

Pregnancy Contraindicated Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly synthesis of other biologically active substances derived from cholesterol (eg, cell membranes), rosuvastatin may cause fetal harm when administered to pregnant women Lactation Contraindicated Limited data indicate that rosuvastatin is present in human milk; because statins have the potential for serious adverse reactions in nursing infants, women who require rosuvastatin treatment should not breastfeed their infants

Interactions

May increase serum levels of warfarin and oral contraceptives. May increase serum levels w/ itraconazole, HIV protease inhibitors. May decrease serum levels w/ erythromycin and antacids. May increase risk of myopathy w/ fenofibrate, niacin. Potentially Fatal: Increased risk of rhabdomyolysis w/ gemfibrozil and ciclosporin.

Adverse Effects

Side effects of Rosuvastatin : >10% Myalgia (3-13%) 1-10% Arthralgia (10%), Diabetes mellitus, new onset (3%), Pharyngitis (9%), Headache (6%), Asthenia (up to 5%), Dizziness (4%), CPK increased (3%), Nausea (3%), Abdominal pain (2%), ALT increased (2%), Constipation (2%), Flulike illness (2%), UTI (2%) <1% Jaundice, Myopathy, Rhabdomyolysis Potentially Fatal: Rhabdomyolysis with acute renal failure.

Mechanism of Action

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. It increases the number of hepatic LDL receptors on the cell surface, enhancing uptake and catabolism of LDL. It also decreases apolipoprotein B, triglycerides and increases HDL.

Note

Zyrosa 12mg Tablets / Film-coated manufactured by Oman Pharmaceutical Products. Its generic name is Rosuvastatin. Zyrosa is availble in United Arab Emirates. Farmaco UAE drug index information on Zyrosa Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Rosuvastatin :

Tablets / Film-coated

Xolstat ^20mg

SUN PHARMACEUTICAL INDUSTRIES LTD

Tablets / Film-coated

Xolstat ^10mg

SUN PHARMACEUTICAL INDUSTRIES LTD